ABBV News

Latest updates and analysis for AbbVie Inc.

February 2026

AbbVie Posts Double Beat for Q4

Q4 EPS $2.71 vs $2.65 est, revenue $16.62B vs $16.42B est; FY26 EPS guidance $14.37-$14.57 vs $14.24 est, signaling robust earnings growth.

Investing.com

NewsFeb 2

AbbVie All In on Obesity

AbbVie signals heavy obesity focus without explicit statement; expected to compete with Novo Nordisk, Merck, Bristol-Myers Squibb, emphasizing efficacy over oral vs. subcutaneous.

Fierce Pharma

January 2026

NewsJan 29

AbbVie at JPM is All In on Obesity

AbbVie expresses enthusiasm for phase 1-2 obesity assets; anticipates big showdown with competitors like Novo Nordisk, Merck, and Lilly in weeks, not months.

BioSpace

NewsJan 28

Biopharma Sentiment Just Snapped Higher

Biopharma sentiment surged with BPSI index jumping 78 to 90; aligns with public market price action and deal flow, expecting continued M&A and IPO activity into summer.

@BowTiedBiotech on X